Hologic, Inc. (HOLX)

68.37 -0.85 (-1.23%) At close: 04:00PM EST

Hologic, Inc.

250 Campus Drive
Marlborough, MA 01752
United States
508 263 2900
https://www.hologic.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 6,990

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen P. MacMillan	Chairman, CEO & President	4.24M	N/A	1964
Ms. Karleen M. Oberton	Chief Financial Officer	1.58M	N/A	1971
Mr. John M. Griffin	General Counsel	1.47M	N/A	1961
Mr. Jan Verstreken	Group President of International	1.24M	N/A	1968
Mr. Paul Malenchini	Chief Information Officer	N/A	N/A	N/A
Ryan M. Simon	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Peter Dunne	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Monica Aguirre Berthelot	VP & Chief of Staff	N/A	N/A	N/A
Mr. Erik Anderson	Division President of Breast & Skeletal Health Solutions	N/A	N/A	1982
Mr. Essex Mitchell	Division President of GYN Surgical Solutions	N/A	N/A	1980

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Corporate governance

Hologic, Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.